MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts

Study Overview
=================
Brief Summary
-----------------
This trial evaluates surgeon-modified fenestrated-branched stent-grafts (sm-FBSG) for Abdominal Aortic Aneurysms (AAA) that are custom-made intra-operatively with no waiting period by a qualified vascular surgeon. In addition, it aims to examine the alternative sm-FBSG for patients with restricted access to centers performing clinical trials with commercially available devices and those patients with aortic emergencies.

Detailed Description
-----------------
Complex aortic aneurysms are those involving the renal and visceral arteries, and open repair of these aneurysms requires more extensive dissection, aortic clamping above the renal or mesenteric arteries, and possible reconstruction of aortic branches. Recovery time tends to be longer, including more hospital days, than for endovascular repair, and there is a greater potential for complications. Many high-risk patients with aneurysms of the abdominal aorta (AAA), including thoracoabdominal aortic aneurysms (TAAA), and significant co-morbidities will be denied elective open surgery because of heightened risks associated with open repair of complex aneurysms, and therefore, the potential benefit of an endovascular option increases as well. Endovascular aneurysm repair has been shown to be an effective alternative in treating uncomplicated infrarenal and thoracic aneurysms in both the elective and urgent setting, yet there is limited experience with this technology in complex conditions. Fenestrated grafts have been developed as a minimally invasive treatment for patients with complex aortic aneurysms who are unfit for traditional open surgery. Surgeon-modified fenestrated-branch stent grafts (sm-FBSG) with branches for the visceral vessels are custom-made by a qualified vascular surgeon for patients with complex aortic conditions. It is expected that they will minimize surgical risks and promote quicker recovery, and they could represent a therapeutic option for high-risk patients unfit for open surgery.

Official Title
-----------------
Surgeon-Modified Fenestrated/Branched Stent-Grafts for Treatment of Complex Aortic Aneurysms in High-Risk Patients

Conditions
-----------------
Complex Aortic Aneurysms

Intervention / Treatment
-----------------
* Device: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria (abbreviated): Patients presenting for elective or urgent repair of a complex aortic aneurysm No other investigational agents or devices while on protocol Patient must be able and willing to comply with all follow-up exams Life expectancy of more than 1 year Patients with medical conditions that would make them unfit for open repair Exclusion Criteria (abbreviated): Estimated life expectancy <1 year Contraindication to angiography Active infection Patients with ruptured or contained ruptured aortic aneurysm who are persistently hemodynamically unstable at the time of presentation Morbid Obesity with inability to visualize the aorta with available intraoperative imaging techniques Anatomic exclusion criteria: iliac arteries and aorta must be able to accommodate endovascular devices and procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)<br> | Device: surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the safety and effectiveness of sm-FBSG for the treatment of complex aortic aneurysms in patients at high-risk for open surgical repair. | Major adverse events defined as: All-cause death Bowel ischemia Myocardial infarction Paraplegia Renal failure Respiratory failure Stroke Blood loss >=1,000cc The primary effectiveness endpoint is the proportion of treatment group subjects that achieve treatment success. Treatment success is a composite endpoint assessed at 12 months that includes successful delivery and deployment of the graft with branch vessel preservation (technical success) as well as freedom from Type 1 and 3 endoleaks, graft migration, and AAA enlargement or rupture. Technical success is defined as successful delivery and deployment of the physician modified endovascular graft with preservation of those branch vessels intended to be preserved. Includes freedom from the following at 12 months: Type I & III endoleak, stent graft migration, AAA enlargement, AAA rupture and conversion to open repair through 12 months. | 30 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate postoperative all-cause morbidity after repair with sm-FBSG | Need for open surgical repair of the aortic aneurysm due to unsuccessful delivery or deployment of the stent graft for any reason Internal bleeding or leaking of blood from the aneurysm subsequent to the index procedure Organ dysfunction | >30 Days to 5 Years | 
| Evaluate long-term survival and complications after repair of complex aortic aneurysms with sm-FBSG | Examination of Internal bleeding or leaking of blood from the aneurysm subsequent to the index procedure Non-diagnostic intervention after the index procedure intended to correct or repair an endoleak, device migration, or other device defect. Clinical evaluation and changes over time. | >30 Days to 5 Years | 
| Successful device delivery and deployment with patency of all branches | Change in aneurysm sac diameter from the first post-procedural measurement; incidence of endoleak, device migration, or limb occlusion Fenestrated stent graft patent luminal flow; absence of stent fracture or graft fatigue/failure Renal and/or Mesenteric Artery and Stent Patency and Integrity | 30 Days, 3 Months, 6 Months, and Years 1 to 5 | 
| Procedural / In-Hospital Evaluations | Organ Perfusion and Function Distal blood flow Fluoroscopy time; contrast volume; estimated blood loss; % requiring transfusion; procedure time; ICU time; time to hospital discharge | 30 Days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sm-FBSG, aneurysms, fenestrated, stent-grafts, Vascular, Endovascular, aortic